Sugi Predict

Sugi Predict / Targets / HNRNPDL

HNRNPDL

Heterogeneous nuclear ribonucleoprotein D-like · O14979 · HNRNPDL on Sugi Atlas →

61 patent compounds predicted against HNRNPDL, 46 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL22024879 SCHEMBL22024879 0.70 1/20
SCHEMBL4698765 SCHEMBL4698765 0.61 1/20
SCHEMBL4700718 SCHEMBL4700718 0.60 1/20
SCHEMBL4699844 SCHEMBL4699844 0.60 1/20
SCHEMBL2806838 SCHEMBL2806838 0.58 1/20
SCHEMBL14070193 SCHEMBL14070193 0.58 1/20
SCHEMBL4697700 SCHEMBL4697700 0.58 1/20
SCHEMBL21943483 SCHEMBL21943483 0.57 1/20
SCHEMBL4697113 SCHEMBL4697113 0.56 1/20
SCHEMBL4699434 SCHEMBL4699434 0.56 1/20
SCHEMBL20558521 SCHEMBL20558521 0.56 1/20
SCHEMBL4697958 SCHEMBL4697958 0.56 1/20
SCHEMBL4754278 SCHEMBL4754278 0.56 1/20
SCHEMBL4700683 SCHEMBL4700683 0.55 1/20
SCHEMBL4787917 SCHEMBL4787917 0.55 1/20
SCHEMBL20558234 SCHEMBL20558234 0.55 1/20
SCHEMBL14070244 SCHEMBL14070244 0.54 1/20
SCHEMBL4785228 SCHEMBL4785228 0.54 1/20
SCHEMBL14070254 SCHEMBL14070254 0.54 1/20
SCHEMBL21943341 SCHEMBL21943341 0.53 1/20

Clinical trials — most relevant to HNRNPDL by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
[18F]ACI-19626 PET in TDP-43 Proteinopathies EARLY_PHASE1RECRUITING
Expression Pattern of HNRNPH1 and HNRNPK Genes in MPNs nanUNKNOWN
Longitudinal Study of Neurogenetic Disorders nanRECRUITING
Diagnosis of Inflammatory Bowel Disease nanNOT_YET_RECRUITING
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis nanCOMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Biocollection in MyeloDysplastic Syndrome (P-MDS) nanRECRUITING
Mechanisms of Cell Death in Spinal Muscular Atrophy nanCOMPLETED
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
Identification of New FTLD Genes nanUNKNOWN
Immunophenotyping and Xist Gene in AML nanUNKNOWN
SMN Circular RNAs as Potential Biomarkers for the Therapeutic Response to Nusinersen in Spinal Muscular Atrophy Patients nanUNKNOWN
Mechanisms of Inherited Retinal Dystrophies Using Whole Genome Sequencing and in Vitro and in Vivo Models nanCOMPLETED
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma nanCOMPLETED
Progression Follow up of the First-degree Relatives of Patients With REM Sleep Behavior Disorder nanUNKNOWN
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients nanUNKNOWN
Na+ Channel mRNA Regulation in Heart Failure nanCOMPLETED
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes nanUNKNOWN
Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer nanCOMPLETED
B3 for NMD: Bench to Bedside and Back nanENROLLING_BY_INVITATION
Pumilio1 (PUM1) Expression, Sickle Cell Anemia, β-thalassemia Intermedia nanNOT_YET_RECRUITING
Amyotrophic Lateral Sclerosis (ALS) Families Project nanRECRUITING
Smoker Extracellular Vesicles Influence on Human Bronchial Epithelial Cells nanCOMPLETED
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma nanACTIVE_NOT_RECRUITING
Risk of HCC in Cirrhotic Patients Post DAAs Ttt nanUNKNOWN
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a HNRNPDL binder may also engage these)

ProteinNameSimilarity
Q3SWU3 — 0.994 Q3SWU3 →
Q60668 — 0.985 Q60668 →
Q7TN99 — 0.984 Q7TN99 →
HNRNPD Heterogeneous nuclear ribonucleoprotein D0 0.983 landscape →
Q6E3D4 — 0.983 Q6E3D4 →
Q6NU14 — 0.983 Q6NU14 →
Q9JJ54 — 0.982 Q9JJ54 →
Q9NFU0 — 0.981 Q9NFU0 →
B3M301 — 0.981 B3M301 →
HNRNPAB Heterogeneous nuclear ribonucleoprotein A/B 0.981 landscape →
Q7TN98 — 0.980 Q7TN98 →
Q8K0V4 — 0.980 Q8K0V4 →
B4JII0 — 0.980 B4JII0 →
Q8K3A9 — 0.980 Q8K3A9 →
B4NBP4 — 0.980 B4NBP4 →
O95343 — 0.980 O95343 →
Q6ZK57 — 0.980 Q6ZK57 →
Q9VIV2 — 0.980 Q9VIV2 →
Q17RY0 — 0.979 Q17RY0 →
Q5ZI72 — 0.979 Q5ZI72 →
A0A0R4IZ84 — 0.979 A0A0R4IZ84 →
Q3U2S4 — 0.979 Q3U2S4 →
Q6E3D2 — 0.979 Q6E3D2 →
P24610 — 0.979 P24610 →
P79832 — 0.979 P79832 →
A2D4R4 — 0.979 A2D4R4 →
Q9AST1 — 0.978 Q9AST1 →
Q8NE35 — 0.978 Q8NE35 →
Q63553 — 0.978 Q63553 →
Q9LJ04 — 0.978 Q9LJ04 →